Supplementary Tables S1-S8 from Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted Therapy

Table S1. Complete clinical, pathologic, and molecular annotations of oncogenic MET fusions Table S2. Summary of reports describing the use of MET-TKI to treat MET fusion-positive malignancies Table S3. Summary of antibodies used for Western blot and immunohistochemistry Table S4. List of genes targeted by DNA and RNA sequencing of 56 tumors with MET fusions Table S5. List of primers and plasmid systems used for transfection experiments Table S6. List of mutations detected in MET fusion-positive tumors Table S7. List of copy number alterations detected in MET fusion-positive tumors Table S8. Additional intergenic structural variants, other than MET, detected in MET fusion-positive tumors